Current Report Filing (8-k)
June 11 2020 - 5:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): June 11, 2020 (April 23, 2020)
BIOTRICITY
INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
000-56074
|
|
47-2548273
|
(State
or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
275
Shoreline Drive, Suite 150
Redwood City, California 94065
(Address
of Principal Executive Offices)
(650)
832-1626
(Registrant’s Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
Securities
registered pursuant to Section 12(b) of the Act: note
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
Securities
registered pursuant to Section 12(b): None
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
|
|
|
|
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[X]
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
April 23rd, 2020, the Board of Directors of the Company appointed Steven Salmon to the Board. There are no arrangements
or understandings between Mr. Salmon and any other persons pursuant to which she was selected as a director,
Mr.
Salmon will receive compensation as a non-employee director in accordance with the company’s non-employee director compensation
practice. Mr. Salmon has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item
404(a) of Regulation S-K. Mr. Salmon has not yet been appointed to any committees of the board.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date:
June 11, 2020
|
|
BIOTRICITY
INC.
|
|
|
|
|
|
|
By:
|
/s/
Waqaas Al-Siddiq
|
|
|
|
Waqaas
Al-Siddiq
|
|
|
|
Chief
Executive Officer
|
Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Dec 2024 to Jan 2025
Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Jan 2024 to Jan 2025
